	US 12,233,130 B2
	Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity
Simon Beaudoin, Sherbrooke (CA)
Assigned to DEFENCE THERAPEUTICS INC., Vancouver (CA)
Filed by DEFENCE THERAPEUTICS INC., Vancouver (CA)
Filed on May 16, 2023, as Appl. No. 18/318,384.
Claims priority of provisional application 63/476,739, filed on Dec. 22, 2022.
Prior Publication US 2024/0207426 A1, Jun. 27, 2024
Int. Cl. A61K 47/68 (2017.01); A61K 47/64 (2017.01)

CPC A61K 47/68033 (2023.08) [A61K 47/645 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); C12N 2710/10322 (2013.01); C12N 2710/10333 (2013.01); C12N 2710/10371 (2013.01)]

19 Claims

1. A multimeric compound comprising two monomers covalently bound to one another via an intermolecular disulfide bond, each monomer comprising a bile acid-peptide conjugate, wherein the peptide comprised in the monomers comprises a nuclear localization signal (NLS), wherein the bile acid comprised in the monomers mediates endosomal escape of the multimeric compound.